3B Pharmaceuticals GmbH (3BP), a private German biotechnology company announced a multi-year collaboration in the field of peptide-led drug discovery with Boehringer Ingelheim.
Under the agreement, 3BP will employ its high-diversity peptide library and hit identification technology on a set of molecular disease targets nominated by Boehringer Ingelheim. Hit compounds identified will be further optimized and jointly characterized by both companies.
Dr. Ulrich Reineke, Managing Director of 3BP stated:
We are very pleased to substantially broaden relationship with Boehringer Ingelheim and confident in adding significant value through our validated peptide hit discovery and medicinal chemistry capabilities.
Financial terms of the collaboration were not disclosed.